Scopus BioPharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alan D. Horsager
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 420 Lexington Avenue New York City NY United States of America 10170
- IPO Date
- Dec 16, 2020
- CIK
- 0001772028
- Website
- scopusbiopharma.com
- Similar Companies
- Business
- Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of transformational therapeutics targeting treatment-resistant cancers and serious diseases with unmet medical needs. The company’s core product offerings center around its proprietary Duet Platform, a suite of bifunctional oligonucleotides designed to activate antigen-presenting cells (APCs) in the tumor microenvironment while alleviating tumor immunosuppression to enhance T cell-mediated immune responses. Key products under the Duet Platform include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02), and CpG-STAT3decoy (DUET-03). DUET-01 is primarily developed as a monotherapy for relapsed or refractory B-cell non-Hodgkin lymphoma, DUET-02 is geared toward systemic delivery for solid tumors such as prostate and kidney cancers, and DUET-03 targets the STAT3 transcription factor protein involved in tumor progression. Scopus BioPharma operates predominantly in the immuno-oncology segment, focusing on gene therapy-based treatments to improve patient outcomes, with activities centered in the United States. Founded in 2016 and headquartered in New York, Scopus BioPharma operates through several development programs and maintains strategic partnerships with leading research institutions, including the City of Hope, the National Institutes of Health (NIH), and Hebrew University, to advance its immuno-oncology therapeutic pipeline. The company has also engaged in recent collaborative research initiatives to expand the clinical application of its Duet Platform therapies in oncology. Recent major developments at Scopus BioPharma include the elimination of certain warrants to purchase approximately 21 million shares, a move aimed at recapitalization to enhance shareholder value. The company’s subsidiary, Duet BioTherapeutics, has presented compelling new data on novel treatments for malignant glioma at prominent immunotherapy conferences in 2024 and 2025, showcasing ongoing advancements in their clinical-stage product pipeline. Additionally, Scopus has prioritized strategic alliances and funding rounds to further support the clinical advancement and commercial readiness of its immuno-oncology gene therapies. Scopus BioPharma serves the biotechnology and pharmaceutical sectors, targeting patients with treatment-resistant cancer types through innovative immunotherapy products. Its specialized focus on bifunctional oligonucleotide therapeutics places it within the broader oncology and gene therapy research fields. The company pursues development primarily in the U.S., with collaborations extending internationally through strategic research partnerships. In summary, Scopus BioPharma Inc. develops and commercializes immuno-oncology gene therapies including the Duet Platform’s bifunctional oligonucleotides for cancer treatment; maintains significant research collaborations; and recently advanced its clinical data presentations and corporate capitalization efforts to support its oncology-focused growth strategy.
Contrasting Scopus BioPharma (NASDAQ:SCPS) & MorphoSys (NASDAQ:MOR)
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
Scopus BioPharma to Present at the LD Micro Main Event
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
Scopus BioPharma Launches Duet Therapeutics
5 Best Penny Stocks To Buy Right Now According To Insiders
Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company